吉西他滨联合紫杉醇治疗老年晚期非小细胞肺癌的疗效与安全性

Effects and safety of pacilitaxelin association with gemcitabine in treating advanced non-small-cell lung cancer in the elderly

目的观察吉西他滨联合紫杉醇（均为抗癌药）治疗老年晚期非小细胞肺癌的疗效与安全性。方法老年晚期非小细胞肺癌35例，吉西他滨1000mg加入生理盐水250mL，静滴45min；紫杉醇120mg加入生理盐水250mL，静滴2h，每3～4周为1周期，其中33例完成3周期化疗。结果在33例中，完全缓解2例（6．06％），部分缓解15例（45．45％），无变化9例（27．27％），疾病进展7例（21．21％），总有效率为51．52％；中位生存时间10个月，中位肿瘤进展时间8个月。不良反应主要表现为骨髓抑制、肝功能损害、脱发、粘膜炎及周围神经毒性。结论吉西他滨联合紫杉醇治疗老年晚期非小细胞肺癌疗效较好，毒性反应较轻。

Objective To evaluate the safety and curative effect of pacilitaxelin association with gemcitabine in treating advanced non-small-cell lung cancer（NSCLC） in the elderly. Methods From may 2002 to april 2008,35 patients were treated with this way, and 33 patients have complished 3 period of chemotherapy . Their clinical data was retrospectively reviewed and analyzed. Results The overall response rate was 51.51% ,including 2 case of cure （6.06%） , 15 cases of marked improvement （45.45%） , 9 cases of failure （27.27%）. The median survial time was 10 months , the median progression time was 8 months, 1 year survival rates were 45.16%. The adverce drug reaction（ADR） ineluded bone marrow depression, liver function damage, alopecia, mucositis and peripheral neurotoxicity. Conclusion Pacilitaxelin association with gemcitabine has a better therapeutic effect in treating advanced NSCLC in the elderly . The ADR is slight.